All Posts: cancer research
-
Countdown to BellRinger: 100 Days Until the Community Bike Ride to End Cancer
Thursday, July 19, 2024, marks 100 days until BellRinger, a bike ride and community movement to end cancer. With efforts to build teams of Riders and fundraising gearing up quickly, BellRinger will take place on October 26, 2024, bringing together Riders of all levels: avid cyclists, casual riders, and people who simply hate cancer – all united in their desire to support cancer research at Georgetown University’s Lombardi Comprehensive Cancer Center, DC’s only cancer center federally designated by the National Cancer Institute.
Category: News Release
-
The Aspirin Conundrum: Navigating Negative Results, Age, Aging Dynamics and Equity
A new study examining the role of aspirin in breast cancer treatment reveals critical issues related to health equity and aging that have broad implications for cancer and other disease intervention trials, say researchers from Georgetown University’s Lombardi Comprehensive Cancer Center. They outline their concerns in an editorial accompanying the study’s findings published April 29 in the JAMA.
Category: News Release
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
For the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining it with a drug that makes cancer cells more responsive to immunotherapy. The research is now in a phase 2 clinical trial being tested in human patients.
Category: Lombardi Stories
-
Understanding Immunotherapy Resistance Leads to New Therapeutic Strategies — and Hope
Samir Khleif, MD, an immunologist and professor of oncology at Georgetown Lombardi, is working to understand why some cancers become resistant to immunotherapy, and how that resistance can be overcome.
Category: Lombardi Stories
-
Ruesch Center Symposium Focuses on Early-Onset GI Cancer
With an emphasis on early-onset gastrointestinal cancer, the 14th Annual Ruesch Center Symposium brought together nearly 300 health care providers, researchers, advocates, patients and caregivers November 16-18 to honor those dedicated to curing GI cancers, discuss the experiences of patients and caregivers, and share the latest research in the field.
Category: Lombardi Stories
-
Computer Models Fill Critical Knowledge Gaps To Help Reduce Cancer Disparities
Reducing health disparities in incidence and mortality for major types of cancers can be aided by sophisticated computer modeling efforts, according to a new, wide-ranging perspective by researchers at Georgetown University’s Lombardi Comprehensive Cancer Center and colleagues. A collection of new studies in the November 8, 2023, special issue of JNCI devoted to cancer disparities modeling outlines a path forward.
Category: News Release
-
Biology Behind New Drug Used to Treat Triple-Negative Breast Cancer Uncovered
How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center.
Category: News Release
-
Researchers Develop Method to Monitor Cancer Radiotherapy Effects at the Cellular Level
Using complex molecular tools, researchers have determined how to measure, in real time, the effect that radiation treatment for cancer can have at the cellular level on surrounding healthy tissue.
Category: News Release
-
Novel Research Shows Older Breast Cancer Survivors Experience Accelerated Aging, Worse Functional Outcomes
In a new multicenter study, researchers from Georgetown University’s Lombardi Comprehensive Cancer Center, the Medical College of Wisconsin (MCW), UCLA and several other leading cancer centers from across the nation examined whether cancer and its treatments accelerate aging. Using novel epigenetic measures to assess biological aging, investigators found that older breast cancer survivors — particularly those exposed to chemotherapy — showed greater epigenetic aging than their same-aged peers without cancer, which may relate to worse outcomes.
Category: News Release
-
Veterans Exposed to Agent Orange May Be at Increased Risk of Developing Progressive Blood Cancers
Research conducted at Georgetown University’s Lombardi Comprehensive Cancer Center and the Washington DC VA Medical Center on a database of veterans exposed to Agent Orange found an association for an increased risk of developing myeloproliferative neoplasms (MPNs), which are acquired stem cell disorders that can lead to overproduction of mature blood cells complicated by an increased risk of blood clots in arteries and veins.
Category: News Release